Corporate Presentation - July 2021 - Investor Overview
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
Corporate Presentation July 2021
Forward-Looking Statements
This presentation contains forward-looking statements about Equillium, Inc. (the Actual results or events could differ materially from the plans, intentions and
“Company”). In some cases, you can identify forward-looking statements by expectations disclosed or implied in the forward-looking statements the
the words “will,” “expect,” “intend,” “plan,” “objective,” “believe,” “estimate,” Company makes due to the risks and uncertainties inherent in the Company’s
“potential,” “continue” and “ongoing,” or the negative of these terms, or other business, including without limitation, risk described in the Company’s filings with
comparable terminology intended to identify statements about the future. the Securities and Exchange Commission (“SEC”). You are cautioned not to
These statements are based on Company management’s current beliefs and place undue reliance on these forward-looking statements, which represent
expectations. These statements include but are not limited to statements the Company’s views as of the date of this presentation. The Company’s
regarding the Company’s business strategy, the Company’s plans to develop anticipates that subsequent events and developments will cause the its views
and commercialize its product candidates, the safety and efficacy of the to change. However, while the Company may elect to update these forward-
Company’s product candidates, the Company’s plans and expected timing looking statements at some point in the future, the Company has no current
with respect to regulatory filings and approvals, size and growth potential of intention of doing so except to the extent required by applicable law. These
the markets for the Company’s product candidates and cash runway. These and other risks and uncertainties are described more fully under the caption
statements involve substantial known and unknown risks, uncertainties and “Risk Factors” and elsewhere in the Company’s filings and reports, which may
other factors that may cause the Company’s actual results, levels of activity, be accessed for free by visiting EDGAR on the SEC web site at
performance or achievements to be materially different from the information http://www.sec.gov and on the Company’s website under the heading
expressed or implied by these forward-looking statements. The Company may “Investors.” All forward-looking statements are qualified in their entirety by this
not actually achieve the plans, intentions or expectations disclosed in its cautionary statement. This caution is made under the “safe harbor” provisions
forward-looking statements, and you should not place undue reliance on the of Section 21E of the Private Securities Litigation Reform Act of 1995.
Company’s forward-looking statements.
2
Equillium Snapshot
World Leaders Validated Strategic Partnership
in CD6 Biology Therapeutic with Biocon Limited
• Developing itolizumab, • Highly differentiated MoA, • Commercial rights to U.S., Canada,
a first-in-class monoclonal inhibiting both the activity and Australia, & New Zealand
antibody targeting the trafficking of T effector cells • Commercial-scale manufacturing
CD6-ALCAM pathway and supply agreement
Strong Cash Balance First-Line aGVHD Proof-of-Concept
• $104.1M 1Q 2021 • Pivotal Phase 3 study to support BLA • PoC studies for SLE/LN and
• Well capitalized to reach • Study initiation planned Q4 2021 uncontrolled asthma ongoing,
near-term catalysts • Potential to be first to market data anticipated 2H 2021
in aGVHD first-line treatment
3
Accomplished Management Team
Dolca Thomas, MD
Bruce Steel, CFA EVP RESEARCH & DEVELOPMENT Steve Connelly, PHD
CHIEF EXECUTIVE OFFICER CHIEF MEDICAL OFFICER CHIEF SCIENTIFIC OFFICER
BioMed Ventures • Rincon Principia • Roche • Pfizer BioMed Ventures • aTyr Pharma
Anaphore • Ambit Bristol Meyers Squibb The Scripps Research Institute
Christine
Zedelmayer Jason Keyes Joel Rothman
CHIEF OPERATING OFFICER CHIEF FINANCIAL OFFICER CHIEF DEVELOPMENT OFFICER
Amylin • Amgen • Ligand Orexigen • Amylin Cytokinetics • Genentech
Amgen • Baxter Raptor • Jazz Pharmaceuticals
Extensive Industry Experience
Rincon
Pharmaceuticals
4
Itolizumab: Pipeline-in-a-Product
Indication Selection Strategy T Cell Mediated Immuno-inflammatory Diseases
Acute Graft-Versus-
Solid Organ Host Disease
Rejection Chronic Graft-Versus-
Host Disease
Strong scientific rationale Multiple Sclerosis Crohn's Disease
Neuromyelitis
Optica Ulcerative Colitis
Robust preclinical / translational data
Uncontrolled Asthma Lupus/Lupus Nephritis
Interstitial Lung
High unmet medical need Diseases
Vasculitis
Scleroderma
Behcet's Disease
Compelling commercial opportunity Atopic Dermatitis
Rheumatoid Arthritis
Psoriasis Psoriatic Arthritis
Uveitis
Current clinical Research Implicates CD6/ALCAM
T cell mediated diseases
development programs pathway in disease pathogenesis
5
Itolizumab Development Overview
Indication Delivery Phase 1 Phase 2 Phase 3 Status, Designations & Catalysts
• Pivotal Phase 3 study to support
acute graft- Pivotal study BLA filing
versus-host initiation expected
disease • FDA Fast Track and Orphan
Q4 2021
Drug Designations
systemic lupus • EQUALISE phase 1b study
erythematosus actively enrolling
(SLE) / lupus • FDA Fast Track Designation
nephritis (LN) • LN interim data expected 2H 2021
• EQUIP phase 1b study
uncontrolled actively enrolling
asthma
• Topline data expected 2H 2021
6
Mechanism of Action
7
CD6-ALCAM Pathway is Central to Immuno-inflammation
APC / TISSUE
CD6 is a co-stimulatory receptor expressed on T cells, differentially
expressed on subsets of innate lymphoid (ILC) and natural killer
(NK) cells, but not on T regulatory cells (Treg)
Activated leukocyte cell adhesion molecule (ALCAM), is
expressed on both antigen-presenting cells and
endothelial/epithelial tissue including the blood-brain-barrier, skin,
gut, lung and kidney
The binding of CD6-ALCAM is important for:
• Immune synapse formation
• Optimal co-stimulation and activation
• Trafficking into tissues
The CD6-ALCAM pathway modulates T cell activity and
trafficking and we believe is central to the pathogenesis of
multiple immuno-inflammatory diseases
T CELL
8
Consuegra-Fernandez et al., Cell Mol Immunol 2018
CD6 Associated With the Amplification of the Auto-reactive Cascade
Highest levels of CD6 are found on activated T effector cells (Teff) and associated
with amplification of the auto-reactive cascade
CD6high CD6low/-
Teff • High Proliferation • Low proliferation
Treg
• Pathogenic Phenotypes • Regulatory phenotype
• Pro-inflammatory cytokines • Anti-inflammatory cytokines
Autoreactive Immune Regulation
“Autoimmunity” “Tolerance”
9
CD6-ALCAM Pathway is Central to Immuno-inflammation
ACTIVITY TRAFFICKING
Increased proinflammatory
cytokine secretion
Optimal immune
synapse formation, Increased
activation trafficking of
and proliferation Teff cells into
target tissues
Suppression of regulatory
pathways 10Itolizumab Reduces Levels of Cell Surface CD6
Levels of CD6 on itolizumab treated cells
normalized to isotype treated cells*
Pathogenic
CD6hi CD4 effector/memory CD8 effector/memory
Teff Cells
(MFI normalized to Isotype)
1.5
(MFI normalized to Isotype)
1.5
Surface CD6 Expression
Surface CD6 Expression
1.0 1.0
Antigenic
0.5
modulation
0.5
0.0 0.0
1 10 100 1000 10000 1 10 100 1000 10000
Incubation Time (Minutes) Incubation Time (Minutes)
CD6lo Non-pathogenic • IgG binds to domain-1 of CD6
Teff Cells
• Dose-dependent loss of CD6 resulting in hyporesponsive T cells
• Pharmacodynamic marker can be monitored in patients
11
* 3 independent experiments on Donor 1041 (unstimulated PBMCs)Unique Upstream, Disease Modifying
Immuno-inflammatory Mechanism
Selectively targets auto-reactive effector T cells, while sparing regulatory
T cells to promote immune tolerance and homeostasis, resulting in durable disease remission
Synergistic inhibition of multiple Inhibition of Teff Restoration of immune regulation
Teff cells and cytokines* trafficking into key without broad immunosuppression
target organs
Teff
Treg Teff
Teff Teff Teff
Teff
Th1 / Th2 / Th17
12
* including but not limited to IFN-γ, TNF-α, IL-4, IL-5, IL-6, IL-13 and IL-17Development
Programs
13aGVHD Overview
Multisystem complication of allogeneic
hematopoietic stem cell transplants (HSCTs)
attacking the recipient’s body 10,000 Allogeneic HSCTs performed in
2020, with incidence increasing
0-100 days post-transplant
30-70% Allogeneic HSCT patients
will develop aGVHD
First-line Steroid-refractory Reported 5 year survival rate for
53% responders to first-line treatment
with corticosteroids
Itolizumab JAKAFI®
Phase 1b/2 Approved
BMTCTN
5% Survival rate for steroid non-
responders
Alpha-1 antitrypsin inolimomab
Phase 3 Phase 3
0 Number of approved treatments
for first-line aGVHD
14EQUATE Study: First-line Treatment of High-Risk aGVHD
Phase 1b open-label, 3x3, dose escalation study of itolizumab
5 doses bi-weekly (days 1, 15, 29, 43 & 57)
Subjects followed through Day 337
1.6 mg/kg
n=6 Primary Objectives
COHORT
33% on
EXPANSION • Assess safety and tolerability
Grade III-IV 1.6 mg/kg steroids ≤3
patients n=3 Grade II days of IV dosing
(AA 2 or 3), • Determine optimal IV dose
III & IV patients
Concomitant
within 72 hours 0.8 mg/kg Concomitant Secondary Objectives
of steroids n=3 within 7 days 0.8 mg/kg • Characterize drug
(2 mg/kg) of steroids n=4
50% on
pharmacokinetics (PK) and
(2 mg/kg)
0.4 mg/kg steroids ≤3 pharmacodynamics (PD)
n=4 days • Assess the clinical activity of
itolizumab: GVHD ORR, CR,
NRM, cGVHD, durability
• Per protocol, 3 evaluable subjects expected in each dose cohort for safety assessment (one year follow-up)
• Evaluable subjects must receive ≥ 2 doses or receive ≥ 1 dose with a DLT in first 29 days
• Continuing to enroll patients; no further dose escalation is anticipated
*Ann Arbor Score: 1, MAP 0.290.
DLT is defined as ≥Grade 3 infusion reaction or clinical finding associated with hypersensitivity or any ≥Grade 3 AE that is
not related to underlying disease that is at least possibly related to study treatment as per the investigator. 15
Data with cut-off date of 30 Apr 2021, subject to change.Efficacy: Responses by Day 15 & Maintained at Day 29
Early Response: Response Endpoint: Treatment Naïve Response:
Day 15 Day 29 Day 29
Treatment ≤3 days on steroids
CR ORR CR ORR N CR ORR
All Subjects, n (%)
0.4 mg/kg (N=4) 2 (50.0) 3 (75.0) 2 (50.0) 2 (50.0) 4 2 (50.0) 2 (50.0)
0.8 mg/kg (N=7) 5 (71.4) 5 (71.4) 5 (71.4) 5 (71.4) 5 4 (80.0) 4 (80.0)
1.6 mg/kg (N=9) 4 (44.4) 7 (77.8) 4 (44.4) 7 (77.8) 5 3 (60.0) 4 (80.0)
TOTAL (N=20) 11 (55.0) 15 (75.0) 11 (55.0) 14 (70.0) 14 9 (64.3) 10 (71.4)
Evaluable Subjects (received ≥ 2 doses), n (%)
0.4 mg/kg (N=3) 2 (66.7) 3 (100) 2 (66.7) 3 (100) 3 2 (66.7) 3 (100)
0.8 mg/kg (N=5) 5 (100) 5 (100) 5 (100) 5 (100) 4 4 (100) 4 (100)
1.6 mg/kg (N=6) 3 (50.0) 5 (83.3) 3 (50.0) 5 (83.3) 5 3 (60.0) 4 (80.0)
TOTAL (N=14) 10 (71.4) 13 (92.9) 10 (71.4) 13 (92.9) 12 9 (75.0) 10 (83.3)
• Six subjects received only one itolizumab dose and were not evaluable per protocol, of which 67% received systemic
steroids for ≥4 days prior to itolizumab dosing
• Discontinuation of study drug after one itolizumab dose due to:
• Requiring subsequent administration of alternate anti-GVHD therapy for progressive disease (n=4)
• Adverse event unrelated to study drug (n=2)
Evaluable subjects must receive ≥ 2 doses or receive ≥ 1 dose with a dose limiting toxicity in the first 29 days.
Abbreviations: ORR=CR+VGPR+PR, overall response rate; CR, complete response; VGPR, very good partial response defined as achieving all the criteria for skin, liver, and
gut involvement per Martin 2009 Consensus criteria without meeting the criteria for CR; PR, partial response. 16
Data with cut-off date of 30 Apr 2021, subject to change.Itolizumab: Clinically Meaningful Complete Responses
in First-line High-Risk* aGVHD
100%
Itolizumab showing improved response at Day 29
GRAVITAS-301 (itolizumab
+ steroids)
Response Rate at Day 29
80% Treatment Naïve
(itacitinib 71% All Subjects
(steroids alone)
+ steroids) ORR (≤3 days on steroids)
CR/ORR CR/ORR
61% 7%
MacMillan 56% ORR 0.4 mg/kg 50%/50% 50%/50%
60% ORR
et al. 2015 0.8 mg/kg
(steroids alone) 80%/80% 71%/71%
43% 19% 1.6 mg/kg 60%/80% 44%/78%
ORR 21% TOTAL 55%/70%
64%/71%
40%
16%
64% • CR’s associated with improved long-term patient
20% 42% outcomes
35%
27%
• Early responses allowed for rapid steroid tapering
0%
N 269 57 57 14 • Adverse events reported with the EQUATE trial have
Treatment Naïve
n/a n/a ≤ 2 days ≤ 3 days been consistent with the safety profile previously
(steroid dose)
partial response reported for itolizumab and those experienced in
very good partial response high-risk aGVHD patients
complete response
*EQUATE high-risk defined as Grade III-IV by MAGIC criteria; 80% of subjects also met Minnesota high-risk criteria used by MacMillan and GRAVITAS-301.
Abbreviations: ORR=CR+VGPR+PR, overall response rate; CR, complete response; VGPR, very good partial response defined as achieving all the criteria for skin, liver, and gut
involvement per Martin 2009 Consensus criteria without meeting the criteria for CR; PR, partial response.
17
MacMillan et al. BBMT 2015; Zeiser et al. EHA Abstract Library 2020.
Data with cut-off date of 30 Apr 2021, subject to change.Itolizumab Associated with Dose Reduction in Systemic Steroid Use
Evaluable Patients
0
% Change from Baseline
0.4 mg/kg (N=3)
-20 0.8 mg/kg (N=4)
1.6 mg/kg (N=6)
in Dose
-40
-60
-80
-100
1 15 29 43 57 85 169
Day
Most subjects maintained steroid reduction from Day 29 and/or continued tapering through Day 169
Data presented as mean (SD); equivalent prednisone dose calculated for methylprednisolone and dexamethasone to determine systemic corticosteroid use at each visit.
Evaluable subjects must receive ≥ 2 doses or receive ≥ 1 dose and have DLT in the first 29 days, who received 1-2 mg/kg prednisone or equivalent at baseline. 18
Data with cut-off date of 30 Apr 2021, subject to change.EQUATE Data: Dose Responsive Reduction of CD6 PD data suggests optimal dose range at 0.8 to 1.6 mg/kg • Itolizumab significantly reduces the surface levels of CD6 on T cells by 24 hours following first dose • At 0.4 mg/kg CD6 trends toward baseline by Day 15; higher doses demonstrate durable CD6 reduction (p
aGVHD Next Steps
Phase 1b Meeting Pivotal study in Submit
data with FDA first-line treatment BLA
1H 2021 Mid-2021 Q4 2021
Goal of conducting a single pivotal trial
to support a biologics license application
(BLA) submission for the indication of
first-line treatment of aGVHD
Proposed protocol and timeline for site initiation and BLA submission contingent on regulatory review and study outcomes
20Lupus Overview
Lupus nephritis: a heterogeneous disease that
is the most frequent and serious manifestation
of systemic lupus erythematosus (SLE) 10,000 Lupus nephritis patients in the U.S.
Targeted Complement
T cell B cell
50-75%
Cytokines Inhibition Of patients do not respond
to frontline treatments
Complement
Teff
40% Of severe, proliferative patients will
progress to end-stage renal disease
Itolizumab BENLYSTA® COSENTYX ® ULTOMIRIS ®
Phase 1b Approved Phase 3 Phase 2
LUPKYNIS ® deucravacitinib GAZYVA® anifrolumab narsoplimab
2 Approved treatments
Approved Phase 2 Phase 3 Phase 2 Phase 2
Product in development designed to
Phase 2
BI 655064
Phase 2
KZR-616
Phase 2
TREMFYA ®
Phase 2
1 modulate both the activity and
trafficking of Teff cells - itolizumab
21EQUALISE Study:
Systemic Lupus Erythematosus & Lupus Nephritis
Phase 1b open-label, dose escalation study
Type B Primary Objective
Type A Cohort 1: 0.4 mg/kg Type A & B
patients with • Assess the safety and tolerability of
patients with active LN with itolizumab in subjects with SLE with and
active or Cohort 2: 0.8 mg/kg inadequate Cohort 1: 0.8 mg/kg
inactive SLE response to without active proliferative lupus nephritis
without LN existing • Determine optimal subcutaneous dose
Cohort 3: 1.6 mg/kg therapies Cohort 2: 1.6 mg/kg
level(s) of itolizumab
2 doses,
day 1 & 14, 13 doses,
subcutaneous Cohort 4: 2.4 mg/kg bi-weekly, Cohort 3: 3.2 mg/kg Secondary Objective
subcutaneous Type A & B
N = 30
Cohort 5: 3.2 mg/kg
• Characterize the pharmacokinetics (PK)
N = 18
and pharmacodynamics (PD) of itolizumab
• Understand changes in disease serologies,
urinary ALCAM and CD6, CD6 receptor
Type A Data Announced
March 30, 2021
occupancy
Type B
• Assess the clinical activity of itolizumab
Type B interim data expected 2H 2021 (Proteinuria and SLEDAI-2K)
22EQUALISE Interim Data: Dose Responsive Reduction of CD6
Reduction in surface levels of CD6 on CD4 cells
Day 15 Day 29
Pre 2nd dose 14 days post-2nd dose
✱✱ ✱✱
✱ ✱✱✱
150 ✱✱ 150 ***pEQUALISE / EQUATE: Comparison of Cell Surface CD6 Level
Comparable potency between intravenous and subcutaneous administration
Cell Surface CD6 Level
fold change from baseline
6 5000
baseline
baseline
SLE 1.6 mpk
5 4000
GVHD 1.6 mpk
CD6 (gMFI)
3000
4
2000
3 1000
2 0
0 10 20 30
1
Study Day
0 10 20 30
Fluorescent detection of cell surface
Study CD6 on CD4 T cells as measured by flow cytometry.
Day
Fluorescence expressed as geometric mean fluorescent intensity (gMFI)
24Therapeutic Limitations: Approved Drugs Hitting a Critical Ceiling
Complete responses critical for renal survival
Survival (%)
100%
60
75%
50%
%
25%
0%
of lupus nephritis
n CR n PR n NR
50 100 150 200
patients are not
Renal survival (censuring for nonrenal death) in patients with severe lupus nephritis based on remission status, NR, no remission
(PALCAM Shown to be a Predictive Biomarker in Active Lupus Nephritis
Unbiased screening of >1100 urinary proteins identified urinary ALCAM as a strong predictor of
disease activity in lupus nephritis patients
Urinary ALCAM Elevated in Active Urinary Biomarker Outperforms Standard Disease Biomarkers in
Lupus Nephritis Lupus Nephritis*
250000
250000
AUC
Distribution of ALCAM levels seen P value Sensitivity Specificity PPV NPV
(95% CI)
* within race and disease severity
Urinary ALCAM pg/mg
200000
200000
Urinary 0.91
< 0.0001 0.91 0.82 0.88 0.86
ALCAM (0.86 – 0.96)
150000
150000
Positive anti-
*statistical significance NA 0.38 0.57 0.57 0.38
dsDNA
100000
100000
Low
NA 0.56 0.55 0.65 0.46
50000
50000 * complement
*
*
*Performance of urinary protein markers in differentiating active lupus nephritis (N=89) from
0
inactive lupus nephritis (N=60) in African American and Hispanic systemic lupus erythematosus
0
Active Active Healthy
Non-Renal
Inactive SLE
Control
patients - UT Southwestern Medical Center, TX
LN
26
Stanley et al., 2016. Comprehensive Aptamer-Based Screening of 1129 Proteins Reveals Novel Urinary Biomarkers of Lupus Nephritis. ACR/ARHP Annual Meeting.Uncontrolled Asthma Overview
A heterogeneous disease characterized by different Teff cell
subtypes & other innate immune cells driving both allergic and
autoimmune mechanisms, leading to chronic airway inflammation
Reciprocally
regulated
2.6M Severe asthma patients
in the U.S.
Th2-Low
Th2-High Non-Th2
1.3M
Low Eosinophils Patients uncontrolled
Eosinophils Neutrophils by standard-of-care
Response to steroids
Current therapies target Current downstream therapies No approved
downstream signaling of ineffective in patients with therapies Of uncontrolled patients who
50%
Th2-associated inflammation low levels of eosinophils
don’t respond to existing
anti-IgE anti-IL-5 anti-IL-4 / IL-13 anti-IL-33 anti-CD6-ALCAM biologics
XOLAIR® NUCALA® DUPIXENT® RG6149 REGN3500 Itolizumab
0 Approved products covering
Marketed Marketed Marketed Phase 2 Phase 2 Phase 1b
Inhaled PI3Kd anti-TSLP
full spectrum of disease
CINQAIR® Anticalin
/AZD1402
Marketed AZD8154 Tezepelumab
Phase 1
Phase 1 Phase 3
Inhaled JAK
FASENRA®
Marketed
JAK1 / AZD0449
Phase 1 27Upregulation of CD6 & ALCAM in Severe Asthma Patients
Examination of lung tissue demonstrates increased CD6,
T cells and ALCAM in the lungs of severe asthma patients
CD6 ALCAM overlay
Fatal asthma patients –
Fatal asthma Non-asthma
lung tissue staining suggests:
• Increased numbers of CD6+ cells
• Upregulation of ALCAM in the lamina
propria (mucosa) epithelium
• Co-localization of CD6+ cells with ALCAM Lamina propria
expressing tissue
Gene expression analysis suggests higher expression of CD6+ T cells
within the airway of patients who have died from severe asthma
Study of the Mechanisms of Asthma (MAST; NCT00595153); Bronchoscopic Exploratory Research Study of Biomarkers in Corticosteroid-refractory Asthma (BOBCAT) study; Data 28
courtesy of Reynold A. Panettieri, Jr., MD, Rutgers Institute for Translational Medicine and Science.EQUIP Study Design: Uncontrolled Asthma
Phase 1b randomized, double-blind, placebo controlled study
Cohort 1: 0.4 mg/kg Primary Objective
Uncontrolled Type A & B
moderate to
severe asthma • Assess the safety and tolerability of
patients Cohort 2: 1.6 mg/kg
subcutaneous dosing of itolizumab in patients
with moderate to severe asthma
5 doses, • Determine optimal subcutaneous dose level(s)
bi-weekly, of itolizumab
subcutaneous Cohort 3: 2.4 mg/kg
Secondary Objective
N = 32 • Characterize the pharmacokinetics (PK) and
Cohort 4: 3.2 mg/kg pharmacodynamics (PD) of itolizumab
• Assess the clinical activity of itolizumab: FEV1,
ACQ, FeNO, Eos
Enrollment ongoing; topline data expected 2H 2021
29Corporate
30Strong Intellectual Property Portfolio / Regulatory Exclusivity
Orphan Designation
7 years
Biologics Exclusivity
12 years in US
Compositions / Methods - U.S. Patent No. 8,524,233
Patent term ~ 2028
Formulations - U.S. 16/197,228
Patent term ~ 2030
Method of Treating MS - U.S. Patent No. 10,189,899
Patent term ~ 2034
Method of Inhibiting CD6 - PCT WO 2018/073721
Patent term ~ 2037
Method of Treating Lupus – U.S. Application 16/343,127
Patent term ~ 2037
Method of Treating Severe Asthma - PCT US2019/019872
Biocon Filings Patent term ~ 2039
Lupus sCD6/sALCAM diagnostic - PCT US2020/019990
Equillium Filings Patent term ~ 2039
Assumptions: New Filing
- Listed applications will issue
- Biologics Exclusivity will be granted and will begin at NDA approval
- Potential patent term extensions not shown New Filing
2006 2010 2014 2018 2022 2026 2030 2034 2038 2042
31Equillium Financial Overview
Key Financial Metrics as of 1Q 2021
Total Cash and Investments $104.1M
Well capitalized to reach
near-term catalysts
Year-to-Date Operating Cash Burn $7.9M
$10.0M
Lean operating model
Outstanding Debt
and disciplined spending
Shares Outstanding 29.0M Operating runway into
$163.8M mid-2023
Market Cap (as of close 12 July, 2021)
Please refer to the Form 10-Q filed on 13 May 2021 for complete financials of
the company as of 31 March 2021
32Multiple Catalysts in 2021
Catalysts & Milestones Timing
EQUALISE Phase 1b study: interim data from Type B patients (lupus nephritis) 2H 2021
EQUIP Phase 1b study: topline data in uncontrolled asthma 2H 2021
Initiate pivotal study in first-line aGVHD Q4 2021
Financed through completion of ongoing clinical trials
with funding in place to advance itolizumab into late-stage development
33Thank you Michael Moore Vice President, Investor Relations & Corporate Communications ir@equilliumbio.com
You can also read
